Cureus
February 1, 2025
Eric Boccio, Jason Haidar, Michael Thiefault et al.
Medical and recreational ketamine use is increasing in the United States; however, little is known regarding the side effects associated with chronic, frequent, and high-dose use. The lack of emergency physician awareness regarding ketamine-induced abdominal pain, nausea, vomiting, and dysuria, collectively and colloquially known as K-cramps, results in delayed recognition, underreporting, and...
Ketamine
2025
Katarina Savić Vujović, Ana Jotić, Branislava Medić et al.
1 citation
Substance use disorders (SUDs), including alcohol, opioid, and cocaine dependencies, present significant challenges in public health. Current treatment modalities often face limitations in efficacy and accessibility, necessitating exploration of novel therapeutic approaches. Ketamine, originally recognized for its anesthetic properties, has garnered attention for its potential in treating SUDs...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Journal of psychopharmacology (Oxford, England)
2025
Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena
20 citations
Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. A comprehensive search was...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2025
Jordi Jornet-Plaza, Sandra Ledesma-Corvi, M Julia García-Fuster
6 citations
While ketamine was approved for treatment-resistant depression in adult patients, its efficacy and safety profile for adolescence still requires further characterization. In this context, prior preclinical studies have shown that sub-anesthetic doses of ketamine during adolescence exert antidepressant-like effects in rodents in a dose- and sex-dependent manner. However, additional studies...
Therapeutic advances in drug safety
2025
Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al.
11 citations
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines and strict...
Frontiers in Psychiatry
2025
Mary R. Shen, Dylan E Campbell, Anika Kopczynski et al.
10 citations
Opioid use disorder (OUD) continues to be a public health crisis in the United States, with mortality having doubled over the last twenty years, leading to significant economic cost, morbidity, and mortality. This has caused significant demand for novel therapeutics. Preliminary evidence demonstrates that ketamine may be helpful in treating OUD as well as serve as an adjunct during treatment of...
Journal of Psychopharmacology
December 17, 2024
Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena
1 citation
Background: Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. Aim: This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. Methods: A...
Journal of Affective Disorders
December 15, 2024
Rodrigo Machado‐Vieira, Gregory H Jones, Alan C. Courtes et al.
Fatigue is a multidimensional condition that may overlap with depression. Initial studies found that fatigue responds in only a limited way to standard monoaminergic antidepressants and mood stabilizers but does respond positively to intravenous (IV) racemic (R,S)-ketamine (ketamine). However, IV ketamine's use is limited by cost and access barriers. To date, no study has evaluated intranasal...
Journal of Psychoactive Drugs
November 22, 2024
Wesley C Ryan, Boris D. Heifets
2 citations
The use of ketamine and ketamine-assisted psychotherapy (KAP) for treatment of depression has grown dramatically, though much of these data are short term. The clinical profile of maintenance treatment remains poorly characterized. We assessed maintenance KAP for efficacy, tolerability, and reasons for dropout. This observational study retrospectively analyzed electronic health records from an...